Technical Analysis for CERO - CERo Therapeutics Holdings, Inc.

Grade Last Price % Change Price Change
F 0.08 -3.15% 0.00
CERO closed down 3.15 percent on Friday, November 1, 2024, on 9 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Up

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
20 DMA Resistance Bearish -3.15%
Wide Bands Range Expansion -3.15%
Up 3 Days in a Row Strength -3.15%
Oversold Stochastic Weakness -3.15%
MACD Bullish Signal Line Cross Bullish 1.96%
Narrow Range Bar Range Contraction 1.96%
Inside Day Range Contraction 1.96%
Wide Bands Range Expansion 1.96%

   Recent Intraday Alerts

Alert Time
10 DMA Resistance about 23 hours ago
Fell Below 10 DMA about 23 hours ago
Gapped Down (Full) 1 day ago
10 DMA Support 1 day ago
Down 5% 1 day ago

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

CERo Therapeutics Holdings, Inc. Description

CERo is an innovative immunotherapy company advancing the development of next generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is expected to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what CERo refers to as Chimeric Engulfment Receptor T cells ("CER-T"). CERo believes the differentiated activity of CER-T cells will afford them greater therapeutic application than currently approved chimeric antigen receptor ("CAR-T") cell therapy, as the use of CER-T may potentially span both hematological malignancies and solid tumors. CERo anticipates initiating clinical trials for its lead product candidate, CER-1236, in 2024 for hematological malignancies.


Classification

Sector: Other
Industry: Other
Keywords: Cancer Solid Tumors Immune System Immunotherapy Treatment Of Cancer Tumor Cancer Immunotherapy Cell Therapy Lymphoma Virotherapy Hematological Malignancies Adoptive Cell Transfer T Cells Tumors Of The Hematopoietic And Lymphoid Tissues Cancer Therapy Car T Cell Treating Cancer

Is CERO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.8
52 Week Low 0.0722
Average Volume 10,264,162
200-Day Moving Average 2.49
50-Day Moving Average 0.10
20-Day Moving Average 0.09
10-Day Moving Average 0.08
Average True Range 0.01
RSI (14) 43.18
ADX 34.74
+DI 30.10
-DI 18.17
Chandelier Exit (Long, 3 ATRs) 0.09
Chandelier Exit (Short, 3 ATRs) 0.11
Upper Bollinger Bands 0.10
Lower Bollinger Band 0.07
Percent B (%b) 0.32
BandWidth 35.14
MACD Line -0.01
MACD Signal Line -0.01
MACD Histogram 0.0007
Fundamentals Value
Market Cap 518.09 Thousand
Num Shares 6.23 Million
EPS -0.35
Price-to-Earnings (P/E) Ratio -0.24
Price-to-Sales 0.00
Price-to-Book 123.73
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.10
Resistance 3 (R3) 0.10 0.09 0.10
Resistance 2 (R2) 0.09 0.09 0.09 0.09
Resistance 1 (R1) 0.09 0.08 0.09 0.09 0.09
Pivot Point 0.08 0.08 0.08 0.08 0.08
Support 1 (S1) 0.08 0.08 0.08 0.08 0.07
Support 2 (S2) 0.07 0.07 0.07 0.07
Support 3 (S3) 0.07 0.07 0.07
Support 4 (S4) 0.07